Correction

Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

Stefano Sestini[1,*], Mattia Boeri[2,*], Alfonso Marchiano[3], Giuseppe Pelosi[4,5], Carlotta Galeone[6], Carla Verri[2], Paola Suatoni[1], Nicola Sverzellati[7], Carlo La Vecchia[8,*], Gabriella Sozzi[2,*], Ugo Pastorino[1,*]

[1]Unit of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

[2]Unit of Tumor Genomics, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

[3]Unit of Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

[4]Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

[5]Department of Clinical and Biomedical Sciences Luigi Sacco, University of Milan, Milan, Italy

[6]Department of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, Laboratory of Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy

[7]Department of Clinical Sciences, Section of Radiology, University of Parma, Milan, Italy

[8]Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

[*]These authors have contributed equally to this work

***Published**: October 15, 2019*

This article has been corrected: In the Introduction section, the second sentence of the second paragraph was worded incorrectly. The proper sentence is as follows:

A significant reduction in lung cancer mortality was reported among the subjects enrolled in the LDCT arm of the National Lung Screening Trial (NLST) when compared to the chest X-ray arm, along with a false discovery rate of 96.4% and an overdiagnosis global rate of 18.5%, reaching 78.9% for indolent cancers in the LDCT arm.

Original article: Oncotarget. 2015; 6:32868–32877. https://doi.org/10.18632/oncotarget.5210